Nuvei (NVEI) delivered earnings and revenue surprises of -30.61% and 5%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...
Northrim BanCorp (NRIM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Revenues are expected to be $7.47 billion, up 1% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 5.61% lower over the last 30 days to the current level.
Some results have been hidden because they may be inaccessible to you